Vasan S. Ramachandran, M.D., Principal Investigator and Director of the Framingham Heart Study (FHS), and Principal Investigator of the Risk Underlying Rural Areas Longitudinal Study (RURAL).
Dr. Ramachandran is a Professor of Medicine and Epidemiology at BUSM/BUSPH, and Chief, Section of Preventive Medicine and Epidemiology, Department of Medicine, BUSM. He is the Jay & Louis Coffman Professor of Vascular Medicine at BUSM. Dr. Ramachandran is a trained cardiologist with subspecialty training in echocardiography. He is a fellow of the AHA Councils on Epidemiology and Prevention and Functional Genomics and Translational Biology, and a fellow of the American College of Cardiology (ACC). He has extensive experience in supervising trainees at many levels and has taught the foundational core course on Cardiovascular Epidemiology at BUSPH (EP751). He has several active R01 grants from the NHLBI/NIDDK/NIA and received two K24 Mid-Career Investigator mentoring grants from the NHLBI. He has mentored several K23 awardees, and is currently the Principal Investigator of a post-doctoral training program (T32) in cardiovascular epidemiology and an R38 (StARR) training program for medicine residents at BUMC. Overall, he has supervised over 75 trainees during the past 20 years (~40% women, 25% non-White); most are in key positions in academia. He received the Outstanding Mentor awards from the Department of Medicine, BUSM, and the AHA Council on Epidemiology and Prevention, the prestigious AHA Population Science Award in 2014 and the AHA Distinguished Scientist Award in 2021.
Importantly, Dr. Ramachandran’s own peer-reviewed funding spans thematic areas of genetics and genomics, cardiac and vascular remodeling, novel biomarkers, systems biology including proteomics and metabolomics, microbiome, and stem cell biology. He has a 25-year history in research in cardiovascular epidemiology, including the two years he trained as a FHS fellow (1993-1995). He established the first School of Public Health in Kerala, India, between 1996-1998, serving as its inaugural director and the coordinator of its MPH program. He is the founding member and leader of the international EchoGen consortium, and chairs the Steering Committee of the Chronic Kidney Disease Biomarker Consortium funded by the NIDDK (U01DK085689). He is recognized internationally for translational research in cardiovascular epidemiology and lectures regularly at the AHA early career session on “how to develop a career in translational research and epidemiology/genetics.” He is a Trained Mentor and has been been a past member of the NIH Cardiovascular and Sleep (CASE) SRG, and an active reviewer of grants for national and international funding agencies. He served for many years on the NHLBI panel for reviewing K23-K24-K25 career development grants. He served as an Associate Editor for Circulation, and the founding Editor-in-Chief of Circulation: Cardiovascular Genetics. He directs the Center for Integrative Transdisciplinary Epidemiology within BUSM, that hosts multiple epidemiological datasets, including from multiple cohort studies, national surveys (NHANES), administrative databases and electronic health records; this center will be a valuable data source for trainees.
For the last 25 years, Dr. Ramachandran has focused his research on A) the genetic and non-genetic epidemiology of congestive heart failure, including identifying risk factors for the disease, characterizing the subgroups with diastolic heart failure, asymptomatic LV systolic and diastolic dysfunction, and evaluating the role of LV remodeling; B) population-based vascular testing and echocardiography, including identifying biological, environmental, and genetic determinants (correlates) of cardiac structure and function; normative standards; detailed assessment of biomarkers of the process of LV remodeling, including but not limited to role of natriuretic peptides, insulin resistance, cardiac extracellular matrix markers, oxidative stress, inflammation, growth factors; genetics of LV remodeling, LA and aortic structure and gene-environment interactions; brachial artery endothelial function, its correlates and tonometric assessment of large artery function; C) genetic and non-genetic epidemiology of high blood pressure, including characterizing the lifetime risk, rates of progression and risks associated with various degrees of elevation; large artery stiffness and function and role in systolic hypertension in the elderly; genetics of high blood pressure and large artery function; D) CVD risk estimation in the short, medium- and long-term, with novel biomarkers including genomic biomarkers; and E) rural health disparities via the RURAL cohort study.
Diversity, Equity, Inclusion and Accessibility
Statement on Diversity, Equity, Inclusion, and Access
Context and understanding. As an immigrant and a foreign-medical graduate from a developing country, I have navigated my professional advancement in the US with a heightened awareness of the challenges encountered by individuals who might be perceived as belonging to a non-majority group. My experiences have sensitized me to the necessity of active, intentional, and ongoing engagement with the diversity of fellow humans and developing a deeper understanding of their lived experiences within institutions, systems, and society. I strive to understand, respect, and celebrate all cultural values and experiences, be authentic about sharing my vulnerabilities, and offer others a ‘safe and brave space’ to voice theirs. I believe that our overall human experiences are richer when we share, assimilate and integrate while maintaining our roots.
My initial medical training in India sensitized me to the critical role of social determinants of health in influencing health care access and disease risk. Working at a tertiary referral care hospital in New Delhi, I daily encountered impoverished patients presenting with very advanced stages of diseases because they could not afford medical care and they delayed seeking care until it was unavoidable. My subsequent work directing the first School of Public Health in Kerala re-emphasized the importance of social determinants of health and structural determinants of equity. Kerala is a beacon for ‘good health at low cost.’ The factors responsible for Kerala’s excellent public health metrics (such as very low infant and maternal mortality rates) include the high level of literacy, the empowerment of women, low levels of child poverty, and a robust network of community health centers that ensure easy access to preventive health care. Working in a developing country has strengthened my belief that diversity, equity, inclusion, and justice are foundational requirements for public health.
Service-related Contributions. As a mentor and a Section Chief, I have embraced mentoring of women, those with a different gender or sexual orientation, and those from a structurally disadvantaged and minoritized background. These experiences have enriched my growth as a mentor. As the Director and PI of two training programs (T32 and R38), I have built mentoring support groups for minoritized scholars within the Department of Medicine at BUSM. I have broadened my search and recruitment strategies of faculty, post-doctoral trainees, and resident scholars using a framework of an inclusive and diverse selection committee and a thoughtful process that prioritizes representation and weights life experiences in parallel with academic credentials. I am actively building relational connections with HBCUs and HSIs for this purpose. As part of an inclusive retention strategy, I advocate for the support, development, and advancement of staff, faculty, and trainees during their employment/training using a framework customized to their individual needs and expectations and informed by their background.
As the Principal Investigator of the Framingham Heart Study (FHS), I have ensured that participants from our modest-sized non-White cohorts are approached with respect, understanding, and recruitment staff who communicate with non-English speakers in their native language. Spanish versions of our consent forms and website facilitate this strategy. I have led efforts to ensure that all FHS data and biosamples requests include our non-White (Omni) cohorts. Researchers have to clarify explicitly if they deviate from our overarching policy of inclusivity. As a study-wide policy, we have assured the representation of biosamples from our non-White cohorts in TOPMed whole genome sequencing and omics-assays. The FHS team (staff and investigators) belong to a diverse group, and we have actively supported funding of diversity supplements.
Research-related Contributions. I have been working with NHLBI non-White cohorts for over two decades. I have co-authored twenty Publications using Jackson Heart Study data, which highlight the burden of cardiovascular disease in Black people. Seminal publications include the development of a cardiovascular disease (CVD) risk prediction score (PMC5115626) and an investigation of the natural history of preclinical heart failure in the cohort (PMC8200743); the latter underscored the substantial burden of preclinical cardiac remodeling in middle-aged Black adults. I am a multi-PI on an NIH grant (R01HL136266), collaborating with the Hispanic Community Health Study and mentoring junior investigators from this study. I am also a multi-PI on another NIH grant (R01HL143295) that returns genetic results (pathogenic variants) to participants in FHS and the Jackson Heart Study. I have advocated for building equitable approaches to returning genetic results to non-White people.
As a scientist, I have directly drawn attention to the importance of addressing health disparities and working towards health equity in my publications and national presentations. In a recent review in the journal Circulation on the future of cardiovascular epidemiology (PMID 34952676), I emphasized the critical need to evaluate and address social determinants of health as upstream mediators of race-related disparities in CVD. Earlier this year, I published a detailed in silico cohort study in a major medical journal (PMC4974092) that drew attention to substantial differences in predicted CVD risk for Black versus White adults with identical risk factor profiles using the AHA pooled cohort equations. I emphasized that these race-related differences in predicted risk were biologically implausible and raised the possibility that using these risk equations can result in racialized approaches to medical decision-making. I questioned the continued use of race as a term in the risk prediction algorithms because it can perpetuate race as a valid medical construct. I suggested (as a possible solution) that causal social determinants of health might be a reasonable substitute for the race term in these risk prediction equations. At a major BUSM CTSI symposium, I explicitly addressed the complex history of recruitment of non-White participants in FHS.
Recently, I designed and funded as the Principal Investigator a new cohort study called the Risk Underling Rural Areas Longitudinal Study (RURAL) to investigate cardiovascular health disparities in the rural Southeastern US. RURAL collaborates with sixteen institutions across the US led by a diverse team of investigators and funded by the NHLBI. RURAL has selected the most economically challenged rural counties in the Southern Appalachia, Mississippi delta, and the ‘Black belt’ to focus its research. One of the main research domains of RURAL is to evaluate structural urbanism in the rural South and investigate rural residence as a ‘meta’ social determinant of health. In its initial 3-year period, RURAL has obtained a diversity supplement and funding for two major ancillary studies led by non-White PIs.
In summary, I stand firmly committed to diversity, equity, inclusion, and justice as a core value of my professional and personal life.
Jay & Louis Coffman Professor of Vascular Medicine
Boston University School of Medicine
Boston University School of Public Health
Boston University School of Medicine
Preventive Medicine & Epidemiology
Principal Investigator & Director; Co-Director, Echocardiography/Vascular Laboratory
Framingham Heart Study
Whitaker Cardiovascular Institute
Evans Center for Interdisciplinary Biomedical Research
Graduate Faculty (Primary Mentor of Grad Students)
Boston University School of Medicine, Graduate Medical Sciences
Computing & Data Sciences Administration
Framingham Heart Study
Framingham Heart Study
Epidemiology of blood pressure responses to perturbations: Correlates and prognosis for vascular risk, end-organ damage, cognitive aging and preclinical Alzheimer's disease
06/01/2022 - 02/28/2027 (PI)NIH/National Institute on Aging1R01AG075703-01
Multidisciplinary Training Program in Cardiovascular Epidemiology
04/01/2021 - 03/31/2026 (PI)NIH/National Heart, Lung, and Blood Institute5T32HL125232-07
Myocardial Radiomics and Mechanics in the Pathology and Prognosis of Cardiovascular Disease
03/15/2021 - 02/28/2026 (Subcontract PI)Beth Israel Deaconess Medical Center, Inc NIH NHLBI1R01HL155717-01
Multidimensional Assessment of Brain Health as A Marker of Dementia Risk and Resilience in the Framingham Study
09/15/2020 - 05/31/2025 (Subcontract PI)University of Texas Health Science Center at San Antonio NIH NIA5R01AG066524-02
RURAL: Risk Underlying Rural Areas Longitudinal Cohort Study
04/01/2019 - 04/30/2025 (PI)NIH/National Heart, Lung, and Blood Institute5U01HL146382-03
Whole-genome sequencing analysis of coronary atherosclerosis and related traits
03/17/2020 - 02/28/2025 (Subcontract PI)University of Texas Health Science Center, Houston NIH NHLBI5R01HL146860-03
PRIMER: Promoting Research In MEdical Residency
07/01/2020 - 06/30/2024 (PI)NIH/National Heart, Lung, and Blood Institute5R38HL143584-02
Plasma Proteome and Risk of Alzheimer Dementia and Related Endophenotypes in the Framingham Study
07/01/2019 - 03/31/2024 (Multi-PI)
PI: Vasan S. Ramachandran, MDNIH/National Institute on Aging1RF1AG063507-01
Return of Genomic Results and Estimating Penetrance in Population-Based Cohorts
08/01/2019 - 06/30/2023 (Subcontract PI)Broad Institute, Inc., The NIH NHLBI5R01HL143295-03
Plasma proteomics in CHS and population biology
07/15/2019 - 06/30/2023 (Subcontract PI)University of Washington NIH NHLBI5R01HL144483-03
Showing 10 of 58 results.
Show All Results
Population-Based Reference Ranges for Estradiol and Estrone in Men
04/07/2012 - 07/31/2012 (Activity-level PI)
PI: Shalender Bhasin, MBBSNIH-NIDDK1R01 DK092938-01A1
Showing 10 of 104 results.
Show All Results
Publications listed below are automatically derived from MEDLINE/PubMed and other
sources, which might result in incorrect or missing publications. Faculty can
to make corrections and additions.
Showing 10 of 804 results.
Lee AM, Hu J, Xu Y, Abraham AG, Xiao R, Coresh J, Rebholz C, Chen J, Rhee EP, Feldman HI, Ramachandran VS, Kimmel PL, Warady BA, Furth SL, Denburg MR. Using Machine Learning to Identify Metabolomic Signatures of Pediatric Chronic Kidney Disease Etiology. J Am Soc Nephrol. 2022 02; 33(2):375-386. PMID: 35017168; PMCID: PMC8819986; DOI: 10.1681/ASN.2021040538;
Vasan RS, van den Heuvel E. Differences in estimates for 10-year risk of cardiovascular disease in Black versus White individuals with identical risk factor profiles using pooled cohort equations: an in silico cohort study. Lancet Digit Health. 2022 01; 4(1):e55-e63.View Related Profiles. PMID: 34952676; PMCID: PMC8715354; DOI: 10.1016/S2589-7500(21)00236-3;
Schmidt IM, Srivastava A, Sabbisetti V, McMahon GM, He J, Chen J, Kusek JW, Taliercio J, Ricardo AC, Hsu CY, Kimmel PL, Liu KD, Mifflin TE, Nelson RG, Vasan RS, Xie D, Zhang X, Palsson R, Stillman IE, Rennke HG, Feldman HI, Bonventre JV, Waikar SS. Plasma Kidney Injury Molecule 1 in CKD: Findings From the Boston Kidney Biopsy Cohort and CRIC Studies. Am J Kidney Dis. 2022 02; 79(2):231-243.e1.View Related Profiles. PMID: 34175376; PMCID: PMC8709877; DOI: 10.1053/j.ajkd.2021.05.013;
Vasan RS, Urbina EM, Jin L, Xanthakis V. Prognostic Significance of Echocardiographic Measures of Cardiac Remodeling in the Community. Curr Cardiol Rep. 2021 06 03; 23(7):86.View Related Profiles. PMID: 34081212
Surendran P, Feofanova EV, Lahrouchi N, Ntalla I, Karthikeyan S, Cook J, Chen L, Mifsud B, Yao C, Kraja AT, Cartwright JH, Hellwege JN, Giri A, Tragante V, Thorleifsson G, Liu DJ, Prins BP, Stewart ID, Cabrera CP, Eales JM, Akbarov A, Auer PL, Bielak LF, Bis JC, Braithwaite VS, Brody JA, Daw EW, Warren HR, Drenos F, Nielsen SF, Faul JD, Fauman EB, Fava C, Ferreira T, Foley CN, Franceschini N, Gao H, Giannakopoulou O, Giulianini F, Gudbjartsson DF, Guo X, Harris SE, Havulinna AS, Helgadottir A, Huffman JE, Hwang SJ, Kanoni S, Kontto J, Larson MG, Li-Gao R, Lindström J, Lotta LA, Lu Y, Luan J, Mahajan A, Malerba G, Masca NGD, Mei H, Menni C, Mook-Kanamori DO, Mosen-Ansorena D, Müller-Nurasyid M, Paré G, Paul DS, Perola M, Poveda A, Rauramaa R, Richard M, Richardson TG, Sepúlveda N, Sim X, Smith AV, Smith JA, Staley JR, Stanáková A, Sulem P, Thériault S, Thorsteinsdottir U, Trompet S, Varga TV, Velez Edwards DR, Veronesi G, Weiss S, Willems SM, Yao J, Young R, Yu B, Zhang W, Zhao JH, Zhao W, Zhao W, Evangelou E, Aeschbacher S, Asllanaj E, Blankenberg S, Bonnycastle LL, Bork-Jensen J, Brandslund I, Braund PS, Burgess S, Cho K, Christensen C, Connell J, Mutsert R, Dominiczak AF, Dörr M, Eiriksdottir G, Farmaki AE, Gaziano JM, Grarup N, Grove ML, Hallmans G, Hansen T, Have CT, Heiss G, Jørgensen ME, Jousilahti P, Kajantie E, Kamat M, Käräjämäki A, Karpe F, Koistinen HA, Kovesdy CP, Kuulasmaa K, Laatikainen T, Lannfelt L, Lee IT, Lee WJ, Linneberg A, Martin LW, Moitry M, Nadkarni G, Neville MJ, Palmer CNA, Papanicolaou GJ, Pedersen O, Peters J, Poulter N, Rasheed A, Rasmussen KL, Rayner NW, Mägi R, Renström F, Rettig R, Rossouw J, Schreiner PJ, Sever PS, Sigurdsson EL, Skaaby T, Sun YV, Sundstrom J, Thorgeirsson G, Esko T, Trabetti E, Tsao PS, Tuomi T, Turner ST, Tzoulaki I, Vaartjes I, Vergnaud AC, Willer CJ, Wilson PWF, Witte DR, Yonova-Doing E, Zhang H, Aliya N, Almgren P, Amouyel P, Asselbergs FW, Barnes MR, Blakemore AI, Boehnke M, Bots ML, Bottinger EP, Buring JE, Chambers JC, Chen YI, Chowdhury R, Conen D, Correa A, Davey Smith G, Boer RA, Deary IJ, Dedoussis G, Deloukas P, Di Angelantonio E, Elliott P, Felix SB, Ferrières J, Ford I, Fornage M, Franks PW, Franks S, Frossard P, Gambaro G, Gaunt TR, Groop L, Gudnason V, Harris TB, Hayward C, Hennig BJ, Herzig KH, Ingelsson E, Tuomilehto J, Järvelin MR, Jukema JW, Kardia SLR, Kee F, Kooner JS, Kooperberg C, Launer LJ, Lind L, Loos RJF, Majumder AAS, Laakso M, McCarthy MI, Melander O, Mohlke KL, Murray AD, Nordestgaard BG, Orho-Melander M, Packard CJ, Padmanabhan S, Palmas W, Polasek O, Porteous DJ, Prentice AM, Province MA, Relton CL, Rice K, Ridker PM, Rolandsson O, Rosendaal FR, Rotter JI, Rudan I, Salomaa V, Samani NJ, Sattar N, Sheu WH, Smith BH, Soranzo N, Spector TD, Starr JM, Sebert S, Taylor KD, Lakka TA, Timpson NJ, Tobin MD, van der Harst P, van der Meer P, Ramachandran VS, Verweij N, Virtamo J, Völker U, Weir DR, Zeggini E, Charchar FJ, Wareham NJ, Langenberg C, Tomaszewski M, Butterworth AS, Caulfield MJ, Danesh J, Edwards TL, Holm H, Hung AM, Lindgren CM, Liu C, Manning AK, Morris AP, Morrison AC, O'Donnell CJ, Psaty BM, Saleheen D, Stefansson K, Boerwinkle E, Chasman DI, Levy D, Newton-Cheh C, Munroe PB, Howson JMM. Publisher Correction: Discovery of rare variants associated with blood pressure regulation through meta-analysis of 1.3 million individuals. Nat Genet. 2021 May; 53(5):762.View Related Profiles. PMID: 33727701
Sanders JL, Putman RK, Dupuis J, Xu H, Murabito JM, Araki T, Nishino M, Benjamin EJ, Levy DL, Ramachandran VS, Washko GR, Curtis JL, Freeman CM, Bowler RP, Hatabu H, O'Connor GT, Hunninghake GM. The Association of Aging Biomarkers, Interstitial Lung Abnormalities, and Mortality. Am J Respir Crit Care Med. 2021 05 01; 203(9):1149-1157.View Related Profiles. PMID: 33080140; PMCID: PMC8314902; DOI: 10.1164/rccm.202007-2993OC;
Tromp J, Paniagua SMA, Lau ES, Allen NB, Blaha MJ, Gansevoort RT, Hillege HL, Lee DE, Levy D, Vasan RS, van der Harst P, van Gilst WH, Larson MG, Shah SJ, de Boer RA, Lam CSP, Ho JE. Age dependent associations of risk factors with heart failure: pooled population based cohort study. BMJ. 2021 03 23; 372:n461.View Related Profiles. PMID: 33758001; PMCID: PMC7986583; DOI: 10.1136/bmj.n461;
Lin BM, Grinde KE, Brody JA, Breeze CE, Raffield LM, Mychaleckyj JC, Thornton TA, Perry JA, Baier LJ, de Las Fuentes L, Guo X, Heavner BD, Hanson RL, Hung YJ, Qian H, Hsiung CA, Hwang SJ, Irvin MR, Jain D, Kelly TN, Kobes S, Lange L, Lash JP, Li Y, Liu X, Mi X, Musani SK, Papanicolaou GJ, Parsa A, Reiner AP, Salimi S, Sheu WH, Shuldiner AR, Taylor KD, Smith AV, Smith JA, Tin A, Vaidya D, Wallace RB, Yamamoto K, Sakaue S, Matsuda K, Kamatani Y, Momozawa Y, Yanek LR, Young BA, Zhao W, Okada Y, Abecasis G, Psaty BM, Arnett DK, Boerwinkle E, Cai J, Yii-Der Chen I, Correa A, Cupples LA, He J, Kardia SL, Kooperberg C, Mathias RA, Mitchell BD, Nickerson DA, Turner ST, Vasan RS, Rotter JI, Levy D, Kramer HJ, Köttgen A, Nhlbi Trans-Omics For Precision Medicine TOPMed Consortium, TOPMed Kidney Working Group, Rich SS, Lin DY, Browning SR, Franceschini N. Whole genome sequence analyses of eGFR in 23,732 people representing multiple ancestries in the NHLBI trans-omics for precision medicine (TOPMed) consortium. EBioMedicine. 2021 Jan; 63:103157.View Related Profiles. PMID: 33418499; PMCID: PMC7804602; DOI: 10.1016/j.ebiom.2020.103157;